Surrozen, Inc./DE (SRZN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 39 days, typically, give or take 22 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Mon, Mar 23, 2026after close 82 8-K
Q3 FY2025Fri, Nov 7, 2025after close 38 8-K
Q2 FY2025Fri, Aug 8, 2025after close 39 8-K
Q1 FY2025Fri, May 9, 2025after close 39 8-K
Q4 FY2024Mon, Mar 31, 2025after close 90 8-K

What they guided beta

Q3 FY2026 "EX-99.1 Exhibit 99.1 Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema DUET Phase 2a enrollment to be expanded from approximately 60 to 150 patients to enable a more robust evaluation of SZN-8141 in DME Topline data from DUET Phase 1b expected in second half of 2027; Phase 2a topline data expected in 2028 Second tranche of March 2025 PIPE and ATM transaction totaling approximately $118.9 million in net proceeds in October 2026 extend anticipated cash run" exhibit
Q3 FY2026 "“The additional capital raised in October positions us to generate a more robust clinical dataset across a broader DME population, while maintaining anticipated cash runway into 2029.”" exhibit
Q3 FY2026 "Strengthened balance sheet through October ATM transaction In October 2026, Surrozen raised approximately $29.8 million in net proceeds through its at-the-market offering program, further strengthening its balance sheet and supporting the expansion of the DUET Phase 2a study." exhibit
Q3 FY2026 "Anticipated cash runway into 2029 The Company anticipates its cash, cash equivalents and marketable securities to provide cash runway into 2029, including funding for completion of the expanded DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143." exhibit
Q3 FY2026 "Topline data from the DUET Phase 1b are expected in the second half of 2027, with topline data from the DUET Phase 2a expected in 2028." exhibit
Q2 FY2026 "EX-99.1 Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pio" exhibit
Q2 FY2026 "Business Highlights, Recent Developments and Upcoming Milestones o The Company continues to advance its ophthalmology pipeline (SZN-8141 and SZN-8143) and expects to submit an Investigational New Drug (IND) application for SZN-8141 by the end of the third quarter of 2026 and initiate the DUET Phase 1b/2a study in diabetic macular edema (DME) patients by year-end 2026" exhibit
Q2 FY2026 "o In June 2026, Boehringer Ingelheim achieved a development milestone under the SZN-413 license agreement following the initiation of a Phase 1 study o In July 2026, the U.S. PTAB denied institution of Merck’s post-grant review petition challenging certain claims of Surrozen’s U.S. Patent No. 12,297,278, determining that the petition failed to show a reasonable likelihood of prevailing with respect to the challenged claims DUET: Phase 1b/2a Clinical Trial in Diabetic Macular Edema SZN-8141 will be evaluated in a Phase 1b/2a clinical trial in DME called DUET, designed to assess safety, tolerabi" exhibit
Q2 FY2026 "DUET is anticipated to initiate by year-end 2026, with initial data expected in the second half of 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SRZN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SRZN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SRZN earnings date badge

HTML

<a href="https://veritasdata.dev/company/SRZN/"><img src="https://veritasdata.dev/embed/SRZN.svg" alt="SRZN earnings date" width="240" height="56"></a>

Markdown

[![SRZN earnings date](https://veritasdata.dev/embed/SRZN.svg)](https://veritasdata.dev/company/SRZN/)

Script

<script async src="https://veritasdata.dev/embed/SRZN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SRZN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.